Figure 1





Figure 2

A


B-cells
T-cells
Monocytes
% Depletion
0
10
20
30
40
50
60
70
80
huCD37-3
huCD37-3-SMCC-DM1
huCD37-50
huCD37-50-SMCC-DM1
TRU-016
rituximab
alemtuzumab

B



B-cells
T-cells
Monocytes
% Depletion
0
10
20
30
40
50
60
70
80
huCD37-3
huCD37-3-SMCC-DM1
huCD37-50
huCD37-50-SMCC-DM1
TRU-016
rituximab
alemtuzumab

Figure 3



A
% depletion
80
60
40
20
0
0.0001 0.001 0.01 0.1 1 10
Ab conc. (μg/mL)
B
% Depletion
70
60
50
40
30
20
10
0
0.0001 0.001 0.01 0.1 1 10
Ab conc. (μg/mL)
C
% Depletion
80
60
40
20
0
-20
0.0001 0.001 0.01 0.1 1 10 100
Ab conc. (μg/mL)
huCD37-3
huCD37-38
huCD37-50
huCD37-56

Figure 4




% Depletion
80
70
60
50
40
30
20
10
0
B-cells
T-cells
NK-cells
Monocytes
huCD37-3
huCD37-3-SMCC-DM1
huCD37-50
huCD37-50-SMCC-DM1
TRU-016
rituximab
alemtuzumab

Figure 5

A


50
40
30
20
10
0
-10
% depletion
0.001
0.01
0.1
1
10
Ab (μg/mL)
huCD37-3
huCD37-3-SMCC-DM1
rituximab

B



40
30
20
10
0
-10
% depletion
0.0001
0.001
0.01
0.1
1
10
Ab (μg/mL)
huCD37-3
huCD37-3-SMCC-DM1
huCD37-50
rituximab

Figure 6



TNF-α
No. spots/5x10E5 PBMC
5200
4200
3200
2200
1200
1000
500
0
0.001 0.01 0.1 1 10 100 1000
Ab conc. (μg/mL)
IFN-γ
No. spots/5x10E5 PBMC
10500
8000
5500
3000
500
500
250
0
0.001 0.01 0.1 1 10 100 1000
Ab conc. (μg/mL)
IL-6
No. spots/5x10E5 PBMC
1400
900
400
400
300
200
100
0
0.001 0.01 0.1 1 10 100 1000
Ab conc. (μg/mL)
huCD37-3
huCD37-3-SMCC-DM1
huCD37-50
huCD37-50-SMCC-DM1
rituximab
alemtuzumab
CD3-2 control
hulgG control

Figure 7



TNF-α
IFN-γ
IL-6
No. spots/5x10E5 PBMC
Ab conc. (μg/mL)
0.001
0.01
0.1
1
10
100
1000
huCD37-3
huCD37-3-SMCC-DM1
huCD37-50
huCD37-50-SMCC-DM1
rituximab
alemtuzumab
CD3-2 control
huIgG control

Figure 8




Geometric Mean Fluorescence
800
700
600
500
400
300
200
100
0
10-12 10-11 10-10 10-9 10-8 10-7 10-6
[Ab] (M)
Kd = 1.4e-8 M

Figure 9

A


Normalized B/T (%)
130
120
110
100
90
80
70
60
50
40
30
20
10
0
mulgG control
3h
5h
1d
3d
7d
8d
10d
14d
post 252-3 Ab injection

B




EAE severity
4
3
2
1
0
0 2 4 6 8 10 12 14 16 18
Days post disease onset
mulgG
252-3 Ab
p = 0.0007

Figure 10

A


Normalized B/T (%)
140
120
100
80
60
40
20
0
mulgG
252-3 Ab
Ab treatment

B





% diabetic
100
80
60
40
20
0
12
14
16
18
20
22
24
26
28
Age (weeks)
mulgG
252-3 Ab
p = 0.0033

Figure 11

A


Normalized B/T (%)
120
100
80
60
40
20
0
muIgG control
1
3
1
Days post
252-3 Ab injection

B


CIA severity
14
12
10
8
6
4
2
0
0 2 4 6 8 10 12 14 16 18 20 22
days post disease onset
muIgG
252-3 Ab
p = 0.0006